AngioDynamics Narrows Net Loss to $8.1M in Q3 FY2026 as Revenue Climbs 9%

AngioDynamics, Inc. (NASDAQ: ANGO), a medical device company specializing in vascular access and oncology products, reported a net loss of $8.1 million for the three months ended February 28, 2026, compared to a net loss of $4.4 million in the same quarter a year earlier. The loss per share widened to $0.19 from $0.11. Read more earnings reports.

Revenue for the third fiscal quarter rose 8.9% to $78.4 million from $72.0 million in the prior-year period. For the nine months ended February 28, 2026, revenue reached $233.6 million, up 10.0% from $212.3 million in the same period of fiscal 2025.

Widening Operating Loss

Operating loss for the quarter came in at $13.0 million, compared to a $10.0 million loss a year earlier. For the nine-month period, the operating loss narrowed to $29.7 million from $34.2 million in the prior year.

Gross profit for the quarter increased to $41.5 million from $38.9 million, while operating expenses rose to $54.4 million from $48.8 million. The gross margin for the quarter stood at 52.9%, up from 54.0% in the prior-year quarter.

Cash Position and Balance Sheet

Cash and cash equivalents totaled $37.8 million as of February 28, 2026, down from $55.9 million at the end of fiscal 2025 on May 31, 2025. The company used $14.4 million in operating activities during the nine-month period, an improvement from $28.9 million in cash used in the prior-year period.

Total assets declined to $260.7 million from $280.1 million as of May 31, 2025. Stockholders' equity stood at $173.4 million, down from $183.0 million at the prior fiscal year-end. Current liabilities decreased to $66.1 million from $76.2 million.

Inventory and Receivables

Accounts receivable rose to $45.6 million from $42.9 million at the end of fiscal 2025. Inventory decreased to $58.6 million from $62.0 million over the same period.

For the nine months ended February 28, 2026, the company recorded depreciation and amortization of $17.4 million, down from $20.0 million in the prior-year period. Research and development expenses totaled $21.3 million for the nine-month period, up from $19.6 million a year earlier.

The company had 41.7 million common shares outstanding as of February 28, 2026, up from 41.0 million at the end of fiscal 2025. Retained deficit widened to $454.5 million from $429.2 million over the same period.